p53腺病毒基因治疗淋巴组织恶性肿瘤的临床疗效探讨  

Observation on the curative effects of recombinant human P53 gene adenovirus in lymphoid tissue malignancies

作　　者：赵芝荣 高娟[3] 董艳迎 谢明[1] 

机构地区：[1]西安交通大学医学院,陕西西安710000 [2]西安凤城医院,陕西西安710000 [3]西安高新医院,陕西西安710000

出　　处：《健康导报（医学版）》2014年第9期245-246,共2页

摘　　要：目的：重组人P53腺病毒注射液（rAd—p53）治疗淋巴组织肿瘤的临床探讨及疗效观察。方法：选择2012年1月到2013年12月，我院常规治疗失败的淋巴组织肿瘤患者42例（其中淋巴瘤患者20例，多发性骨髓瘤患者22例），采用rAd—p53髓内注射基因治疗一个疗程以上，通过临床观察治疗前后机体T细胞亚群及骨髓涂片肿瘤细胞的比例变化，评价rAd—p53治疗淋巴组织肿瘤的临床疗效。结果：rAd—p53注射液治疗多发性骨髓瘤后，CD4＋细胞与CD56细胞较治疗前有显著升高，细胞数基本恢复到正常水平，CD8＋细胞较治疗前显著下降。但仍高于正常对照组（P〈0．05）。淋巴瘤患者治疗后，T细胞亚群较治疗前无显著变化。多发性骨髓瘤骨髓涂片结果显示。rAd—p53三次治疗后浆细胞的比例均较治疗前显著下降（P〈0．05）。淋巴瘤的骨髓涂片结果显示，三次治疗后淋巴瘤细胞的比例均与治疗前无显著性差异（P〉0．05）。结论：rAd—p53注射液对于多发性骨髓瘤患者的治疗效果明显优于淋巴瘤患者。Objective： To explore the effects of recombinant human P53 gene adenovirus （ rAd - I053 ） inthe treatment of lymphoid tissue malignan- cies. Methods： 42 cases failed in the routine surgery （20 lymphoma cases; 22 multiple myeloma cases） were selected from inpatients with lymphoid tissue tumor between January 2012 and December 2013. 42 cases were performed tad - p53 intramodullary injection more than one course. The change of T cells subsets and the percent of tumor ceils in bone marrow smears were evaluated before and after treatment. Results： The level of CD4 ＋ and CD56 in- creased obviously to almost normal levels after rAd - p53 treatment in multiple myeloma cases （ P 〈0.05 ）. The levels of CD8 ＋ cells decreased significantly, but still higher than normal control. In lymphoma cases, T cells subsets had no noticeable changes. In bone marrow smears of multiple myeloma cases, the percent of plasrna cells had declined significantly after treatment. However, lymphoma ceils in bone marrow smears of lymphoma cases had no significantly change compared with pre - treatment. Conclusion：The therapeutic efficacy of rAd - 1353 in multiple myeloma cases was significantly better than lymphoma cases.

关 键 词：淋巴组织肿瘤 重组人P53 腺病毒 多发性骨髓瘤 淋巴瘤 

分 类 号：R730.5[医药卫生—肿瘤]